C.T. Fitzpatrick’s Biogen BIIB Stock Holding History

C.T. Fitzpatrick’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-750	Closed	-$230K	–	58
2015 Q4	$230K	Buy	+750	New	+$216K	﹤0.01%	54

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

C.T. Fitzpatrick's BIIB Position: Q1 2016 in Review

C.T. Fitzpatrick sold out of Biogen (BIIB) in Q1 2016, closing a stake of 750 shares — an estimated $230K sold.

C.T. Fitzpatrick first reported a position in BIIB in Q4 2015 and held it in 1 quarter. The position peaked at $230K in Q4 2015. 948 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

C.T. Fitzpatrick reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
C.T. Fitzpatrick sold 750 Biogen shares in Q1 2016, an estimated $230K.
C.T. Fitzpatrick first reported a position in Biogen in Q4 2015 and held it in 1 quarter.
C.T. Fitzpatrick's Biogen position peaked at $230K in Q4 2015.
948 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Vulcan Value Partners's 13F filing for Q1 2016, filed 18 May 2016.